semaglutide description Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an increasingly popular medication for improving glycemic control and promoting weight loss in patients with type 2 diabetes or obesity. Although gastrointestinal symptoms FLOWing with the SemagluTIDE —

4 The accompanying GOV.UK patient page, last updated in February 2026, sets out the washout periods clearly: semaglutide-based medications need at least two months, tirzepatide (Mounjaro) needs at least one month, and liraglutide can be stopped just before trying because it leaves the body much more quickly

Long-Term Gastroparesis While GLP-1 inhibitors can slow stomach emptying, this effect does not necessarily indicate long-term gastroparesis

Chemotherapy-induced peripheral neuropathy Four randomized controlled trials (RCTs) have evaluated the use of acetyl-L-carnitine (LC) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)

Some semaglutide weight management trial data and product information report hair loss at low incidence, with higher reporting in people who lose more weight